Chronic progressive multiple sclerosis

This study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…

This study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Research…

This study followed 134 adults in Italy with active secondary progressive multiple sclerosis who were prescribed siponimod (Mayzent) as part of their routine care. Over 36 months, researchers measured how many patients experienced a confirmed worsening of disability or cognitive …

This study tested a treatment called extracorporeal photopheresis (ECP) in 15 people with multiple sclerosis. ECP is a procedure that filters a person's blood, treats it with light, and returns it to the body. The goal was to see if it is safe and if it can improve walking, hand …

This early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available ye…

This study looked at how well ofatumumab works in 562 people with relapsing multiple sclerosis who switched from other drugs (fumarates or fingolimod) because their disease was still active. The main goal was to see how many relapses they had per year. Researchers also tracked si…

This study tested an experimental drug called BIIB091, alone or combined with an approved MS drug (diroximel fumarate), in 127 people with relapsing multiple sclerosis. The goal was to check safety and see if it reduces brain inflammation on MRI scans. Participants took pills twi…

This study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …

This early-stage trial tested a new cell therapy called DUOC-01, made from donated umbilical cord blood, in 20 adults with primary progressive multiple sclerosis (PPMS). The cells were injected into the spinal fluid to see if it was safe. Researchers also looked for early signs o…

This Phase 3 trial tested whether the oral drug tolebrutinib can delay disability progression in people with primary progressive multiple sclerosis (PPMS). 767 adults with PPMS received either tolebrutinib or a placebo. The study measured time to confirmed disability worsening ov…

This study looked at how ocrelizumab, a standard MS medication, changes brain inflammation in 22 people with multiple sclerosis. Researchers used special PET and MRI scans to measure inflammation before and after one year of treatment. The goal was to see if the drug reduces harm…

This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…

This study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…

Researchers tested an artificial intelligence program that analyzes retinal images to diagnose several nerve and brain conditions, such as optic neuropathy and brain tumors. The study used data from 693 patients with confirmed diagnoses. The goal is to create a fast triage tool f…

This trial investigates whether a non-invasive technique called transcranial direct current stimulation (tDCS) can help with fatigue, depression, anxiety, and cognitive problems in people with multiple sclerosis (MS). tDCS uses a weak electrical current applied to the scalp to ge…

This study tested whether a 12-week exercise program using coordinated arm movements could improve brain function and movement in people with progressive multiple sclerosis (MS). Five adults with progressive MS did the exercises three times a week. Researchers measured brain acti…

This study looked at whether a diet low in salt and sugar can reduce common side effects of corticosteroid treatment, such as weight gain, high blood pressure, and diabetes. Fifty adults with autoimmune diseases or asthma who were starting high-dose corticosteroids were randomly …

This study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …

This study used advanced MRI scans to look at energy use in the brains of 40 people with multiple sclerosis and 15 healthy volunteers. The goal was to see if energy problems in brain cells can predict nerve damage over two years. Researchers hope this will help understand how MS …

This study looked at over 13,000 people with chronic inflammatory rheumatism or autoimmune diseases who had or were suspected to have COVID-19. Researchers tracked how many developed severe COVID-19 requiring intensive care or leading to death. They also examined risk factors lik…

This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of dise…

This completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers …

This study tested whether home automation and remote monitoring can help elderly people (65+) with multiple chronic conditions live safely at home. Over 500 participants had their homes equipped with sensors that tracked health signs and sent alerts to doctors. The main goal was …

This study looked at 46 people with progressive multiple sclerosis who have more weakness on one side of their body. Researchers used MRI scans to see how damage in the brain and spinal cord relates to muscle strength in each limb. The goal was to better understand what causes ph…

This study analyzed MRI scans from 732 people with primary-progressive multiple sclerosis who took part in the ORATORIO trial. Researchers wanted to see if ocrelizumab changes a part of the brain called the choroid plexus, which may be involved in inflammation. The study was obse…

This study aimed to translate and validate an Italian version of a tool that helps speech therapists assess swallowing difficulties (dysphagia) in people with neurodegenerative diseases like Parkinson's or ALS. Researchers tested the tool on 101 adults with such conditions to ens…

This completed study looked at how different types of brain damage—from strokes, tumors, infections, or degenerative diseases—affect thinking and memory. Researchers used brain scans (MRI) and cognitive tests in 346 patients and healthy volunteers to map which brain areas are res…

This completed survey looked at whether healthcare professionals and people with multiple sclerosis (or their caregivers) understand the safety steps needed when using the drug Mayzent (siponimod). Over 300 participants from Europe answered questions about proper use, side effect…

This completed observational study followed 367 people with relapsing-remitting or active secondary progressive multiple sclerosis who were taking Kesimpta for the first time. Researchers tracked side effects and how well the drug worked in everyday use. The goal was to gather re…

This study reviewed medical records of 800 multiple sclerosis patients to see if gender, race, or socioeconomic status affected how quickly they started Ocrelizumab or how well it worked. Researchers looked at relapse rates and MRI changes over 12 to 24 months. The goal was to id…

This early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather…

This study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…

This completed study measured two proteins in the blood—neurofilament light chain and GFAP—that can signal nerve damage. Researchers compared 15 people with atypical MS, 30 with typical MS, and 15 healthy controls to see if these markers differ. The goal was to better understand …

This study looked back at medical records of 606 people with secondary progressive multiple sclerosis (SPMS) in Russia who were taking siponimod. Researchers wanted to understand patient characteristics and how the drug was used in everyday practice. The study collected data from…